Objective: To determine the impact of intake occasion (with or without a meal), and product fat level on the cholesterollowering efficacy of a plant sterol (PS)-enriched (3 g/day) single-dose yoghurt drink. Design: Double-blind, randomized, placebo-controlled, parallel study with a 4 weeks run-in and 4 weeks intervention period. Setting: Subjects recruited from the general community. Subjects: A total of 184 moderate hypercholesterolaemic subjects (81 men and 103 women) (age 5772 years) completed the study. Interventions: The study product was a 100-g single-dose yoghurt drink with or without added PS in the form of PS esters. The subjects were randomly assigned to one of five 4-week treatments: (i) drink A (0.1% dairy fat, 2.2% total fat) with a meal, (ii) drink A without a meal, (iii) drink B (1.5% dairy fat, 3.3% total fat) with a meal, (iv) drink B without a meal and (v) placebo drink with a meal. Results: LDL-cholesterol (LDL-C) was significantly lowered when the single-dose drink was taken with a meal independent of its fat content (drink A: À9.5% (Po0.001, 95% CI: À13.8 to À5.2); drink B: À9.3% (Po0.001, 95% CI: À13.7 to À4.9)) as compared to placebo. When consumed without a meal, LDL-C was also significantly decreased (drink A: À5.1% (Po0.05, 95% CI: À9.4 to À0.8); drink B: À6.9% (Po0.01, 95% CI: À11.3 to À2.5) as compared to placebo, however the effect was significantly smaller as compared to the intake with a meal. Conclusion: These results indicate that a PS-ester-enriched single-dose yoghurt drink effectively reduces LDL-C irrespective of the fat content of the product. A substantially larger decrease in serum cholesterol concentration was achieved when the singledose drink was consumed with a meal emphasizing the importance of the intake occasion for optimal cholesterol-lowering efficacy.
Introduction
Many studies have shown that plant sterol (PS)-enriched foods significantly lower total cholesterol (TC) and lowdensity lipoprotein cholesterol (LDL-C) concentrations in different population groups independent of their background diets (Weststrate and Meijer, 1998; Hendriks et al., 1999; Maki et al., 2001; Nestel et al., 2001; Ntanios et al., 2002; Cleghorn et al., 2003) . Recently, a meta-analysis of 41 studies concluded that the optimal daily intake of PS or stanols (the saturated form) is 2-2.5 g/day, which results in a reduction in LDL-C of about 10% (Katan et al., 2003) . Longterm efficacy studies lasting up to 1 year have shown that the LDL-C-lowering effect is sustained when PS-or stanolenriched foods are regularly ingested (Miettinen et al., 1995; Hendriks et al., 2003) . Initially, PS were incorporated into fat-based foods such as spreads and margarine in the form of PS esters due to an increased solubility. Nowadays, alternative PS-enriched low-fat or nonfat foods such as milk, yoghurt and orange juice are available and thus offer a wider range of food choices, which fit within current dietary recommendations for the prevention of coronary heart disease (CHD).
The main mechanism of action for the cholesterol-lowering effect of PS resides within the gastrointestinal tract.
Although not all the details are fully elucidated, several mechanisms are thought to contribute to the overall reduction of intestinal cholesterol absorption and hence the cholesterol lowering action of PS. The classical suggested mechanism of action is displacement of cholesterol from the micellar phase. As there is limited capacity in dietary mixed micelles to embody PS, the micellar concentration of cholesterol is reduced and, hence, its transport towards the intestinal brush border membrane is decreased (Trautwein et al., 2003; Mel'nikov et al., 2004) . Further, stimulation of bile flow as a response to fatty food intake seems crucial in view of the formation of dietary mixed micelles and thus plays a critical role in the overall mechanism of action and consequently also for the cholesterol-lowering potential of PS when consumed with various background diets and as different enriched food formats.
Recently, several studies have shown that consumption of PS-enriched low-fat or nonfat foods like bread, cereals, milk, yoghurt or orange juice significantly lowered TC and LDL-C, demonstrating their cholesterol-lowering efficacy (Nestel et al., 2001; Mensink et al., 2002; Spilburg et al., 2003; Clifton et al., 2004; Devaraj et al., 2004; Thomsen et al., 2004; Noakes et al., 2005) . However, a few studies have suggested that the cholesterol-lowering effect of PS may be weakened when provided as low-fat or nonfat foods and beverages (Denke, 1995; Jones et al., 2003) implying that optimal efficacy is not always achieved with such food formats. It has been suggested that the optimal cholesterol-lowering effect may depend on the physical form of the PS formulation, the solubility in the food matrix, and possibly on the fat content of the particular food or its consumption with regular meals as part of the daily diet. Specifically, how the food matrix and the occasion of intake influence the cholesterol-lowering effect of a PS-enriched, low-fat food are less defined aspects. Although in several studies PS-enriched foods have been consumed either with or without a meal in conjunction with different background diets, no study has examined the importance of the occasion of intake of a low-fat food format by directly comparing consumption with a meal or between meals, for example, as a stand-alone, meal-free event.
Regarding the optimal number of servings per day, this aspect was addressed in only one study, while most studies have been performed with PS consumed in two or three daily portions. A daily intake of 2.5 g/day of esterified plant stanols in the form of a spread either consumed once per day with lunch or divided into three portions per day and consumed with breakfast, lunch and dinner resulted in a similar 9-10% reduction in TC and LDL-C (Plat et al., 2000) . A similar cholesterol reduction was also found with a single daily dose of 2.7 g/day of PS in ground beef (Matvienko et al., 2002) . Nevertheless, the majority of studies demonstrating the cholesterol-lowering efficacy of PS-enriched foods relied on two to three servings per day, which has led to the more prudent recommendation of consuming PS in at least two servings per day (FDA, 2000) .
Ingesting PS in the form of a single-dose, low-fat yoghurttype drink is a new concept in view of being a concentrated source of PS delivered in a small volume as compared to multiple intakes of larger servings of dairy-type foods or fruit juices. Hence, the potential cholesterol-lowering effect needs substantiation.
Therefore, the aim of the present study was to demonstrate the effect of two different fat levels (based on 0.1% dairy fat and 1.5% dairy fat) of a PS ester-enriched yoghurt single-dose drink on plasma lipid and lipoprotein cholesterol concentrations in mildly hypercholesterolaemic subjects. In addition, special attention was given to the occasion of intake by investigating the effect of consuming the single-dose drink either in a fasted state, that is, in the morning before breakfast on an empty stomach versus with a meal, that is, together or right after eating lunch.
Materials and methods

Study design
The study was a randomized, double-blind, placebo-controlled, parallel intervention study performed at the Unilever Health Institute, Vlaardingen, The Netherlands. The study was conducted following the guidelines of Good Clinical Practice (ICH-GCP).
The subjects were randomly allocated to one of the five treatments. Drink A and B contained B3 g of PS, but different in the dairy and total fat content.
Drink A (0.1% dairy fat, 2.2% total fat) consumed with a meal.
Drink A (0.1% dairy fat, 2.2% total fat) consumed without a meal.
Drink B (1.5% dairy fat, 3.3% total fat) consumed with a meal.
Drink B (1.5% dairy fat, 3.3% total fat) consumed without a meal.
Placebo drink (based on 1.5% dairy fat) consumed with a meal.
Intake occasions were defined as without a meal by consuming the drink at least half an hour before breakfast in the morning or with a meal by consuming the drink with or immediately after eating lunch. Participants were requested to consume one 100-g serving of the single-dose drink per day at the instructed intake occasion.
The treatment period lasted 4 weeks following a 4-week run-in period, in which the subjects were encouraged to minimize changes in composition of their habitual dietary habits to provide a baseline measurement of TC concentrations. The total study duration was 8 weeks. For practical reasons, the study was conducted in two cohorts starting 1 day apart.
Study product
The study products were yoghurt drinks manufactured under factory conditions. The products (placebo and PS esterenriched) were supplied in coded, blank 100-g plastic bottles for daily consumption. The actual PS dose in the products was 3.2 g in drink A and 2.8 g in drink B. Tall oil sterol esters (tall oil sterols esterified with fatty acids from sunflower oil) were used. The PS composition of the products was as follows (wt% of total sterol content, in descending order): sitosterol (78.7%); sitostanol (8.9%); campesterol (7.7%); stigmasterol (1.1%); campestanol (1.0%); D5-avenasterol (0.6%); brassicasterol (0.1%); other sterols (1.4%). The fatty acid composition of the products (weight % of total fatty acids) for the PS ester-enriched drinks A and B and placebo drink, respectively, was as follows: o16:0 (0.8, 10.3, 28.8); 16:0 (7.0, 15.2, 29.4); 18:0 (4.2, 6.9, 11.4); 18:1(incl. isomers) (25.9, 25.0, 22.6); 18:2 (incl. isomers) (60.0, 39.3, 3.2); 18:3 (incl. isomers) (0.8, 0.7, 0.3); 418:0 (0.8, 0.6, 0.1); sum of all trans fatty acids (2.2, 3.0, 4.1); and other fatty acids (0.7, 2.1, 4.2). The nutritional composition of the study products is given in Table 1 .
Directly after production and during the experimental period the products were analysed. Before the study, the stability of the drinks was checked. The fatty acid composition of the study products was obtained after extraction of the fat phase according to the reference method using the procedure described by de Koning et al., 2001 . The total PS content of the products was determined after extraction and gas chromatography according to a method similar to that described previously for spreads and fat blends (Duchateau et al., 2002) .
Study participants
Participants were recruited among inhabitants from the town of Vlaardingen and surroundings through public advertisement and by approaching subjects who participated in previous studies at the study centre. Subjects were selected based on screening values for mean fasting TC between 5.0 and 8.0 mmol/l (193 and 309 mg/dl), mean fasting triacylglycerol (TAG) o4.0 mmol/l (354 mg/dl), body mass index X18.0 kg/m 2 and o32.0 kg/m 2 , no use of lipid lowering medication or medication potentially affecting the study measurements, supplements or a diet known to affect serum lipids. Subjects had not donated blood at least 4 weeks (men) or 8 weeks (women) before the start of the study, and had not participated in another biomedical study in a period of 3 months before the start of the study. A total of 468 subjects were screened and 200 subjects were included in the study, dropouts were not replaced. Nine subjects withdrew during the run-in period for medical and personal reasons. At the start of the treatment period, 191 subjects were randomly assigned to one of the five intervention groups. Participants were informed about the study and all subjects signed an informed consent form before participation. The study was approved by the Medical Ethical Committee of Wageningen University (approved February 2004) . The baseline characteristics of study participants are shown in Table 2 . There were no differences in baseline characteristics between groups. 
Dietary background and dietary restrictions
During the study (run-in and intervention periods) participants were instructed to maintain their habitual lifestyle and dietary habits (eating and drinking habits and activity pattern). They were requested to avoid the intake of any PSor stanol-enriched food, to use the same brand of cooking and bakery products and spreads and were asked to refrain from taking any cholesterol-lowering supplements or medication during the study. Throughout the study subjects recorded illnesses, medicine use, any important deviations from their lifestyle, dietary and activity pattern. Adverse events (AE) were classified according to ICD-9. At the start and end of the intervention period, body weight was measured.
Compliance was assessed with the help of a questionnaire in which subjects reported daily whether they had consumed the drink, the time of consumption, the time of breakfast and lunch and possible deviations from their background diet. Data completeness and the adherence to intake occasion were evaluated by one or the researchers regularly throughout the study.
A full assessment of dietary intakes was not done. Nevertheless, to estimate the fat intake with habitual lunch and to assess whether this would affect cholesterol-lowering efficacy, the subgroup of subjects who consumed the drink together with lunch were asked about their usual lunch habits on weekdays. This was done at the end of the study with the help of a food questionnaire. A dietician checked the questionnaire in presence of the subject to ensure completeness and consistency. Based on available data about the habitual Dutch lunch habits and the data from the questionnaire, a dietician estimated the fat intake in grams consumed with a typical lunch over the past 4 weeks during the intervention period. These data were used to assess whether the amount of fat consumed with a usual lunch would affect the magnitude of reduction in serum cholesterol concentrations when the single-dose yoghurt drink was consumed with or directly after lunch.
Laboratory measurements
Two blood samples for serum lipid analyses were taken with 1 day in between at the end of the 4-week run-in period (baseline) and at the end of the 4-week intervention period. Before blood sampling, subjects were fasted and had refrained from food for at least 10 h. Venous blood samples (5 ml) were taken into plain tubes. Blood samples were centrifuged for 10 min at 3000 r.p.m. at 221C to separate serum from red blood cells and serum was stored at À701C until analysed. Serum lipids (TC, LDL-C, HDL-C and TAG) were measured by standard methods. Serum TC (intra-/ interassay coefficient of variation (CV): 0.9%; 1.1%), serum HDL-C (intra-/interassay CV: 1.5%; 1.4%), serum LDL-C (intra-/interassay CV: 2.3%; 1.7%) and serum TAG (intra-/ interassay CV: 1.2%; 4.4%) were analysed in duplicate with standardized reagents using a Hitachi 912 Autoanalyser (Roche Diagnostics, Basel, Switzerland), following the recommended kit procedures. The mean of the duplicate analysis was used for data evaluation. The auto analyser was calibrated before each run based on a standardization protocol.
Statistical analyses
The number of subjects was calculated taking into account a critical difference in LDL-C of 0.3 mmol/l. between one of the four intervention groups and the control group with a ¼ 5% and a power of 80%. Under these constraints, 32 volunteers per treatment or 160 in total were required. Assuming a 20% dropout rate, 40 volunteers per group were considered, thus 200 in total were required to start the study.
All results are presented as means7s.e.m.'s and with 95% confidence intervals (CI) where appropriate. Differences were considered significant at Po0.05 unless stated otherwise. The comparisons were made using the mean lipid value of the two measurements taken at baseline and the end of the intervention period.
The statistical analyses were performed on the individual data by using a general linear model with factors treatment and gender. Differences between treatments were analysed using a multiple comparison test according to Dunnett (onesided). Main effects due to meal and fat content and their interaction were analysed by extending the analysis to a factorial model. Data analyses were performed using SAS version 8.2 (SAS Institute, Cary, NC, USA).
Results
Study participants
A total of 186 out of 191 participants who started the intervention period (97%) completed the study. During the intervention period, five subjects were excluded for medical reasons (e.g., medication intake likely to affect lipid metabolism) or difficulties with compliance. Two participants were excluded from data analyses due to a conflict with dietary or medical limitations of the study, leaving 184 (81 men and 103 women) that were included in the data analyses. During the study, there was no significant change in body weight or BMI. At the end of the treatment period, the mean body weight was 74. 
Compliance
Compliance was considered high, as except for some minor deviations all participants consumed the test products as instructed and no changes in background diet were noted. The intake of the single-dose drink reached the target of one 100-g serving per day resulting in a daily PS intake of 3.2 g for drink A and 2.8 g for drink B. Compliance with the instructed intake occasion was high. In the group of subjects who consumed the product at least half an hour before breakfast, no deviations were reported. In the group consuming the drink with or directly after lunch, 15 subjects indicated to have taken the product more than 1 h after lunch at one of the intervention days.
The incidence and prevalence of AE was not significantly different between groups. Headache and nasopharyngitis were the most frequently observed AE. Headache was reported by 16 subjects (8% of all subjects). Nasopharyngitis was reported by 13 subjects (7% of all subjects).
Dietary fat intake with a typical lunch
In the subgroup of subjects (n ¼ 110) who consumed the drink with their habitual lunch, the typical fat intake with lunch was assessed. There was no significant difference in the fat intake with lunch between the groups or between genders. On average, the mean fat intake with a typical lunch was 2272 g with a range from 7 to 42 g. Typical fat intake was 2372 g for drink A, 2172 g, for drink B and 2272 g for the placebo drink.
The amount of fat consumed with a usual lunch did not affect the magnitude of reduction in LDL-C after the intake of drink A and drink B (Figure 1 ).
Serum lipids
The mean serum lipid concentrations at baseline and after the 4-week consumption of the placebo drink and drink A and B are shown in Table 3 . In the placebo group, serum TC concentrations increased slightly, while in the groups consuming drink A and drink B either with or without the Figure 1 Change in LDL-cholesterol concentrations (mmol/l) after the intake of a placebo and plant sterol-enriched single-dose yoghurt drink consumed with lunch in relation to the estimated fat intake (in grams) with a habitual lunch. Significantly different from the placebo treatment at week 4 *Po0.05, **Po0.01, ***Po0.001. There was a significant effect due to intake occasion, for example, with or without a meal, but no effect due to the fat content of the drink or an interaction. The PS-enriched drinks significantly lowered TC and LDL-C concentrations as compared to the placebo drink. LDL-cholesterol was lowered by 0.4070.07 and 0.377 0.06 mmol/l, respectively, with drinks A and B, when they were taken with lunch. Consumed without a meal, drink A decreased LDL-C by 0.2170.06 mmol/l and drink B by 0.2970.08 mmol/l as compared to placebo. The mean percentage change in serum lipid concentrations and the 95% CI after intake of the PS-ester drinks as compared to the change in the control group are shown in Table 3 . Compared to placebo, LDL-C was significantly lowered when the singledose yoghurt drinks were consumed with lunch, independent of their fat content. LDL-C was also significantly reduced when the single-dose drinks were taken without a meal, but the effect was smaller compared to consumption with a meal. As the fat content of the PS-enriched drinks did not affect the cholesterol-lowering efficacy, data from drink A and B were combined to emphasize the impact of the intake occasion on the cholesterol-lowering efficacy. Comparing the changes observed between the intake with lunch versus intake without a meal revealed a significant difference in the reduction of TC and LDL-C (Figure 2 ).
Discussion
The daily intake of a PS-enriched single-dose yoghurt drink delivering around 3 g/day of PS effectively lowered TC and LDL-C concentrations independent of its fat content as compared with a placebo single-dose yoghurt drink. At both intake occasions, the PS-enriched drink significantly lowered TC and LDL-C concentrations, while a larger effect on TC and LDL-C was seen when the PS-enriched drink was consumed in the fed stage, that is, taken with or directly after lunch (À9.4%) as compared to the intake without a meal, for example, before breakfast on an empty stomach (À6.0%). This resulted in a significant difference in the cholesterol-lowering efficacy of the PS-enriched single-dose yoghurt drink between the two intake occasions with an enhanced cholesterol-lowering effect when the drink was consumed as part of a meal.
The actual daily intake of PS with the two drinks was 3.2 g for drink A and 2.8 g for drink B. One could argue that the difference in PS dose between the two drinks might have affected the outcome as a higher dose could have led to a more pronounced cholesterol-lowering effect, thus making a comparison between the two drinks less valid. Nevertheless, considering the dose response of the cholesterol-lowering effect of PS, it is well established that the effect tapers off at intakes around 2 g/day and that doses higher than 2.5 g/day add little extra benefit (Katan et al., 2003) . Therefore, it is unlikely that the difference in PS dose between drink A and drink B affected the observed reductions in TC and LDL-C and hence combining data of the two drinks to compare the impact of intake occasion is justifiable. It is also not likely that the daily PS dose of around 3 g triggered the study outcome. Two recent studies demonstrating the cholesterollowering efficacy of 2 g/day of stanols taken in the form of a single-dose yoghurt drink reported similar reductions of LDL-cholesterol in the range of 8.4-11.3% (Pineda et al., 2005; Salo and Wester, 2005) .
The effect found in this study with a single-dose yoghurt drink is consistent with the reported cholesterol lowering effects of other dairy-based foods, such as milk or yoghurt (Beer et al., 2001; Volpe et al., 2001; Mensink et al., 2002 Thomsen et al., 2004; Noakes et al., 2005) . In these studies, a reduction in LDL-C ranging from 5 to 16% with a PS or stanol intake of 1-3 g/day was found. However, none of these previous studies have tested the single-dose concept as milk and yoghurt were typically consumed in multiple servings per day. To our knowledge, it has never been studied before in a systematic way whether ingesting a PS-containing food product in a fed or a fasted state affects the cholesterol-lowering effect, or at least it has so far not been reported to affect efficacy. Many of the recent studies that investigated the cholesterol-lowering effect of PS or stanols incorporated into low-fat foods and beverages have reported that the food products have been taken with a meal or as part of a meal. This has been the case for the following food products: cereal and bread (Nestel et al., 2001) , lemonade (Spilburg et al., 2003) , milk and yoghurt (Mensink et al., 2002; Clifton et al., 2004; Thomsen et al., 2004) and orange juice (Devaraj et al., 2004) . Further, a greater effectiveness of consuming plant sterols daily with every meal versus the same dose every other day has been reported in an animal study (Hayes et al., 2002) . A significantly larger cholesterol-lowering effect was observed when the PS-enriched single-dose yoghurt drink was consumed in conjunction with a meal. This suggests that a fed state is crucial for an optimal cholesterol-lowering efficacy.
Considering the mechanisms of action of PS through the reduction of intestinal cholesterol absorption, it seems plausible that factors affecting gastrointestinal transit time as well as triggering bile flow can have an impact on the cholesterol-lowering efficacy when a food product is taken as a stand-alone, meal event-free occasion. Several mechanisms may explain this association. Firstly, the ingestion of a fatty meal stimulates bile flow and this results in a maximal release of (endogenous) cholesterol into the gut lumen. The digestion of food is linked to fat emulsification with the help of bile and pancreatic enzymes. PS esters are involved in this process and thus interact with the micellar cholesterol from both dietary and endogenous sources (Rigler et al., 1986; Evans and Wennerström, 1994; Ostlund, 2002; Trautwein et al., 2003; Mel'nikov et al., 2004) . A reduction of the cholesterol content in dietary mixed micelles due to a dynamic competition between cholesterol and PS for the micellar solubilization is an important part of the overall mechanisms of action of PS.
Secondly, it seems plausible that when taken with a regular meal, preferably an energy-dense meal, the gastric emptying may be prolonged over a longer time period, approximately with a rate of 1.5-2.0 kcal/min as has been suggested (Daugherty and Mrsny, 1999) . Thus, this will delay and sustain in time any digestive process taking place in the intestinal lumen. Both mechanisms together seem essential for an optimal situation for PS to interact with micellar cholesterol over time and consequently for maximal displacement of dietary and biliary cholesterol from the micellar phase. As a consequence, the intestinal cholesterol absorption will be more efficiently reduced and hence more cholesterol will be excreted in the faeces (Trautwein et al., 2003) . Also, it cannot be fully ruled out that differences in cholesterol intake with meals could have influenced the observed effects. For Dutch men and women, the typical cholesterol intake with lunch is about 72 and 53 mg, respectively, while with breakfast this is about 27 and 20 mg, respectively. However, based on daily cholesterol intakes of 254 mg for men and 203 mg for women, both breakfast and lunch contribute only modestly to the total daily intake. Moreover, these amounts are considered small in comparison to the daily biliary cholesterol output of 600 mg up to 1 g.
It could be argued that a liquid food might not be the best food vehicle for PS enrichment as compared to a solid food matrix considering that the time constraint of the micellization process plays an important role in the mechanism of action of PS.
Gastric emptying of a liquid phase of a meal is more rapid than of a solid phase (Maes et al., 1998) . Therefore, PS consumed as part of a slow emptying solid food have more time to be mixed with the intestinal contents and hence can better interfere with micelle solubilizaton. Nevertheless, when consuming a liquid PS-enriched food with a meal, preferably a fat-rich or energy-dense meal, such barriers may become less important as our study has clearly demonstrated that consuming the single-dose drink with lunch enhanced the cholesterol-lowering effect as compared to taking the drink in a fasted condition.
It has been suggested that, at least with free, unesterified PS or stanols, the efficacy in lowering total and LDL-C may depend on the physical form of the PS formulation, their solubility in the food matrix, and possibly also on the fat content of the food.
Recently, it was shown that unesterified PS when incorporated into nonfat and low-fat containing beverages modestly decreased plasma cholesterol concentrations; however, there was no significant difference in the effect between the placebo, low-fat and nonfat beverages . The beverages used in that study contained either no fat or 1 g of fat per 100-g serving. Subjects consumed three of such 100-g servings per day. To further investigate such a potential influence of the fat content of the food product on the cholesterol-lowering efficacy in our study, single-dose yoghurt drinks that differed in their fat content were tested. The amount of total fat per 100-g serving was 2.2 g for drink A and 3.3 g for drink B with the majority of fat coming from the fatty acid moiety for the PS esters. The two single-dose yoghurt drinks, even when consumed on an empty stomach, significant lowered TC and LDL-C as compared to placebo. A direct comparison between the two drinks with different fat levels did not show a significant difference, suggesting that the fat level of the product is less important for optimal cholesterol lowering efficacy. However, it cannot be ruled out that the difference of about 1 g in the fat content between the two drinks may have been too small to actually observe an impact on product fat level.
Based on these findings it can be speculated that a fat content of a food item above 2 g seems already sufficient, even when consumed without a meal to trigger enough secretion of bile flow, a crucial step for the formation of dietary mixed micelles that plays an important role in the overall mechanism of action of PS and consequently for their optimal cholesterol reduction. It has been shown that a liquid meal containing less than 1 g fat did not stimulate sufficient gall bladder emptying, while 10 g of fat was enough to produce a maximal stimulus (Stone et al., 1992) . Therefore, a fat content of a food product of above 2 g might be around or above a threshold level for sufficient gall bladder emptying and hence bile secretion. This assumption is further supported by the fact that the amount of fat required with a meal for optimal carotene absorption and uptake is considered to be in the range of 3-5 g (RibayaMercado, 2002) . Carotenoids are known to rely also on dietary mixed micelles formation for efficient uptake from the gut. Furthermore, comparing our findings with those of Jones et al. (2003) may demonstrate a benefit of PS esters over free PS, as proper solubility becomes less of an issue. Thus, PS esters appear to be the preferred choice to achieve optimal reduction in plasma cholesterol, although recently free PS or stanols applied in the form of phosholipid micelles finely dispersed, or dissolved and then recrystallized in oil have been found to be efficacious (Spilburg et al., 2003; Devaraj et al., 2004; Hayes et al., 2004; Thomsen et al., 2004) . However, in these studies, the foods enriched with such PS formulations have been taken with meals.
Our study was designed with free-living conditions and participants were asked to consume their habitual diet with only some minor restrictions throughout the study. Although a full dietary assessment was not carried out, the average amount of fat eaten with a usual lunch was estimated and found to be 2272 g, which is comparable to the fat intake with a Dutch standard lunch. The estimated daily fat intake with lunch varied from 7 to 42 g, demonstrating a wide interindividual variation in lunch habits. Assessing whether the amount of fat eaten with the usual lunch had affected the magnitude of LDL-C lowering with the PS-enriched single-dose yoghurt drink showed no such association. Taking the limitations in estimating the fat intake with lunch into account, the finding may suggest that a similar cholesterol lowering effect can be achieved irrespective of a low or high amount of fat eaten with a meal, provided it is above a certain threshold level, probably in the range of only a few grams. However, from our findings it cannot be ultimately concluded whether the amount of fat is the only critical factor or rather the protein content or even the energy density of the meal. Both digestible fat and protein are major stimuli for the release of cholecystokinin (CCK) after a meal and thus gall bladder contraction and bile secretion (Hopman et al., 1985) .
In conclusion, this placebo-controlled parallel study demonstrated that a PS-enriched single-dose yoghurt drink effectively lowered TC and LDL-C concentrations irrespective of the fat content of the product. The reductions found are similar to those reported from recent studies testing a single-dose intake of stanols in the form of a yoghurt drink (Pineda et al., 2005; Salo and Wester, 2005) .
However, when the drink was consumed as part of a meal, a significantly larger reduction in total and LDL-C was achieved as compared to taking the drink before breakfast on an empty stomach. This emphasizes the importance of the intake occasion. Thus, for optimal efficacy, a PS-enriched single-dose yoghurt drink should be consumed with a regular meal as part of a healthy diet. Incorporating PS into a low-fat yoghurt single-dose drink seems an attractive, convenient and easy concept to lower modestly elevated cholesterol concentrations by dietary means.
